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Abstract
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is thought to play modulatory roles in the development
of atherosclerosis. Here we evaluated the effects of a specific lp-PLA2 inhibitor on atherosclerosis in ApoE-deficient mice and
its associated mechanisms.
Methodology/Principal Findings: ApoE-deficient mice fed an atherogenic high-fat diet for 17 weeks were divided into two
groups. One group was administered the specific lp-PLA2 inhibitor, darapladib (50 mg/kg/day; p.o.) daily for 6 weeks, while
the control group was administered saline. We observed no differences in body weight and serum lipids levels between the
two groups at the end of the dietary period. Notably, serum lp-PLA2 activity as well as hs-CRP (C-reactive protein) and IL-6
(Interleukin-6) levels were significantly reduced in the darapladib group, compared with the vehicle group, while the serum
PAF (platelet-activating factor) levels were similar between the two groups. Furthermore, the plaque area through the arch
to the abdominal aorta was reduced in the darapladib group. Another finding of interest was that the macrophage content
was decreased while collagen content was increased in atherosclerotic lesions at the aortic sinus in the darapladib group,
compared with the vehicle group. Finally, quantitative RT-PCR performed to determine the expression patterns of specific
inflammatory genes at atherosclerotic aortas revealed lower expression of MCP-1, VCAM-1 and TNF-a in the darapladib
group.
Conclusions/Significance: Inhibition of lp-PLA2 by darapladib leads to attenuation of in vivo inflammation and decreased
plaque formation in ApoE-deficient mice, supporting an anti-atherogenic role during the progression of atherosclerosis.
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Introduction
Atherosclerosis is the most common cause of cardiovascular
diseases, such as myocardial infarction and stroke. The develop-
ment of atherosclerosis is associated with both lipids metabolism
and inflammation [1].
Lp-PLA2, also designated platelet-activating factor acetylhy-
drolase (PAF-AH; E.C. 3.1.1.47), is a special Ca
2+-independent
phospholipase associated mainly with apoB-containing lipopro-
teins and primarily with LDL in humans [2]. Epidemiological
studies have suggested that elevated circulating lp-PLA2 is
predictive of increased cardiovascular risk [3]. Lp-PLA2 is up-
regulated by oxidized phospholipids in oxLDL, and in turn, acts
on these oxidized phospholipids (oxPCs) to produce two pro-
inflammatory mediators, lysophosphatidylcholines (lysoPCs) and
oxidized non-esterified fatty acids (oxNEFAs) [4]. There is
considerable evidence to support regulatory roles of these two
products, particularly lysoPCs, in promoting atherosclerotic
plaque development. For instance, lysoPCs can recruit leukocytes
to lesions, activate leukocytes to initiate immune responses, and
promote foam cell formation [5,6].
The in vitro and ex vivo findings collectively suggest a causative
role of lp-PLA2 in the development of atherosclerosis, and
inhibition of its activity may thus induce beneficial effects. An
earlier study reported that the lp-PLA2 inhibitor, darapladib,
reduces complex coronary atherosclerotic plaque development in
pigs with induced diabetes and hypercholesterolemia [7]. Dar-
apladib has additionally shown beneficial effects in clinical studies.
The compound attenuates the inflammatory burden in patients
with stable coronary heart disease and prevents necrotic core
expansion, a key determinant of plaque vulnerability [8].
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PLA2 inhibitor on atherosclerosis development in mouse models.
This may be due to two reasons. Firstly, the lipid profile and
distribution of lp-PLA2 in plasma of mice are distinct from those in
humans [9]. Lp-PLA2 is mainly associated with HDL in mice and
LDL in humans, and its role in atherosclerosis may thus differ,
depending on the lipoprotein carrier in plasma [10]. Secondly,
other in vivo experiments in mice have suggested an anti-
atherogenic role of lp-PLA2. Specifically, adenovirus-mediated
gene transfer of human lp-PLA2 prevented injury-induced
neointima formation and reduced spontaneous atherosclerosis in
ApoE-deficient mice as well as accumulation of oxidized
lipoproteins, and inhibited inflammation and thrombosis in non-
hyperlipidemic rabbits [11,12].
In this study, we examined the effects of the lp-PLA2 inhibitor,
darapladib, in ApoE-deficient mice to further establish its role in
development of atherosclerosis.
Materials and Methods
Animals and experimental protocol
Male homozygous ApoE-deficient mice (C57/Bl6 genetic
background) were obtained from the Jackson Laboratory. The
following protocols were approved by the Animal Care and Use
committee of the Shanghai Institute of Materia Medica, Chinese
Academy of Sciences (Approval ID: SIMM-AE-WYP-2010-03).
The cages (length is 280 mm, width is 165 mm, high is
135 mm) with toys inside were used to contained less than 5 mice,
all animals were housed in a temperature (21–26uC), humidity
(40–70%), and light-cycle controlled( Light was on between 7:00
am and 7:00 pm) room. Mice were fed a high-fat diet (containing
18% hydrogenated cocoa butter, 0.15% cholesterol, 7% casein,
7% sucrose, and 3% maltodextrin) for 17 weeks, starting at 6
weeks of age. Fifty mice were divided into two groups randomly
(N=25 per group). One group received darapladib (50 mg/kg/.
p.o.) once daily, while the other group received vehicle. During the
6 weeks of treatment, all mice allowed free access to a high-fat diet
and water.
Serum lipid analysis
Mice were anesthetized slightlyby diethyl ether when blood
samples were obtained from the retroorbital plexus before drug
administration and 24 hours after the last drug administration.
Serums were acquired through centrifugation of the blood samples
at 4uC at 1000 g, and stored at 280uC until analysis. Total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG)
levels were measured enzymatically with commercial kits from
Wako Inc. using an auto-analyzer (Hitachi 7100, Japan).
Serum lp-PLA2 activity was measured using 2-thio-PAF as the
substrate. Ten mL of serum was added to 0.1 M Tris-HCl (PH 7.2)
containing 1 mM EGTA, 50 mM 2-thio-PAF and 10 mLo f2m M
5,59-dithio-bis-(2-nitrobenzoic acid) in a total volume of 200 mL.
The assay was performed using a plate reader to obtain
absorbance values at 414 nm every minute. The lp-PLA2 activity
was calculated from the change in absorbance per minute
(Cayman Chem. Lot 76091).
Serum IL-6, hs-CRP, and PAF levels were determined by
ELISA according to manufacturers’ instructions (Mingrui Biotech.
Inc.).
Morphology of atherosclerotic plaques
After 6 weeks of treatment, mice were anesthetized by diethyl
ether and sacrificed. The mice were dissected and aortas were
perfusion-fixed with 4.5% formaldehyde. Then the aortas were
dissected, from the heart to approximately 3 mm distal to the iliac
bifurcation. The aortas were preserved in fresh paraformaldehyde
solution for 2 weeks and Sudan IV staining was employed to
determine the plaques on entire aortas. Briefly, after removing
surrounding adventitial fatty tissue, the aortas were opened
longitudinally and pinned out on a black silica gel plate. The
aorta was rinsed in 70% ethanol after 12 hours of fixation in the
paraformaldehyde solution, stained with 1% Sudan IV in 50%
acetone/35% ethanol for about 10 minutes, and washed in 80%
ethanol for 5 minutes. Finally, the stained aortas were photo-
graphed and analyzed using the Image Pro-Plus 6.0 software.
Immunohistochemistry
Paraffin sections through the aortic sinus were obtained and
used to quantify the lesion composition. Briefly, paraffin sections
were deparaffinized, rehydrated, and subsequently treated with
0.3% H2O2 for 10 minutes to abolish endogenous peroxidase
activity, and 5% BSA for 1 hour to block non-specific antibody
binding. Subsequently, sections were incubated overnight at 4uC
with murine smooth muscle actin antibody (1:50 dilution,
Beyotime Biotech Inc.) or Mac-2 antibody (1:50 dilution, Santa
Cruz Inc.), respectively. After washing, sections were incubated
with secondary antibodies for 1 hour at room temperature and
finally visualized with a DAB kit (Beyotime Biotech Inc.). For
collagen determination, Masson trichrome staining was per-
formed, according to the manufacturer’s instructions (Genmed
Inc.).
Quantitative RT-PCR
After 6 weeks of treatment, total RNA was extracted from the
aortic arch and thoracic-abdominal aortas of the two groups of
mice using TRIZOL reagent (Invitrogen Inc.). First-strand cDNAs
were synthesized from 4 mg of total RNA using M-MLV reverse
transcriptase (Promega Inc.). Quantitative real-time PCR was
performed using SYBR Green I as the detector dye. Relative gene
expression was calculated by normalizing to the quantity of mouse
actin gene. Primers’ sequences are shown in Table S1.
Statistical analysis
Data are presented as mean values 6 SEM. For serum lipids
and lp-PLA2 activities, comparisons were made using one-way
analysis of variance (ANOVA), followed by the post-hoc Dunnett
test for significance. Comparisons of body weight, plaque area and
gene expression were made using the two-tailed Student’s t-test.
For all tests, P,0.05 was considered statistically significant.
Results
Darapladib inhibits mouse serum lp-PLA2 activity in vivo
We examined a range of darapladib concentrations to determine
the dose inducing inhibition of mouse plasma lp-PLA2 before
continuous administration, and found the dosage of 50 mg/kg.p.o
inhibits the plasma lp-PLA2 activity remarkably (Figure 1A). Thus,
the dose was chose to administrate the ApoE-deficient mice during
the whole periods. As shown in Figure 1B, plasma lp-PLA2 activity
was inhibited by more than 60% after oral administration of
50 mg/kg of darapladib once daily for 6 weeks.
Inhibition of lp-PLA2 has no significant effects on the
serum lipid profile
The serum lipid level and body weight were evaluated in both
groups. As expected, we observed no significant differences in the
Lp-PLA2 Inhibition and Atherosclerosis
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23425Figure 1. Darapladib significantly inhibits serum lp-PLA2 activity in ApoE-deficient mice. (A). Five apoE-deficient mice were
administrated with darapladib (50 mg/kg p.o.) and serum lp-PLA2 activity before or 1, 3, 6, 12, 24 hours after administration was measured. (B).
Serum lp-PLA2 activity was measured using spectrometry before and at the end of drug administration. **p,0.01 vs. vehicle at 6 weeks. and *p,0.05
vs. vehicle at 0 week.
doi:10.1371/journal.pone.0023425.g001
Table 1. Effects of inhibition of lp-PLA2 by darapladib on body weight (g), serum total cholesterol, triglyceride, HDL-C and LDL-C
levels (mM) in ApoE-deficient mice.
Body weight Total cholesterol Triglyceride HDL cholesterol LDL cholesterol
Vehicle 31.660.7 45.4461.49 1.7060.06 2.3060.15 36.6761.53
Darapladib 30.160.9 48.1962.01 1.7460.12 2.4860.15 37.4062.00
N=25 per group.
doi:10.1371/journal.pone.0023425.t001
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darapladib-treated ApoE-deficient mice. Additionally, the body
weights of ApoE-deficient mice in both groups were similar
(Table 1).
Inhibition of lp-PLA2 triggers decreases in serum
inflammatory markers
Lp-PLA2 is considered a novel anti-atherosclerosis target from
the inflammatory viewpoint. Accordingly, we evaluated the serum
levels of two typical inflammatory markers, hs-CRP and IL-6,
using ELISA. Levels of both hs-CRP and IL-6 were significantly
reduced in the darapladib group, compared with those in the
vehicle group of ApoE-deficient mice (Figures 2A and 2B). As
mentioned above, lp-PLA2, also named PAF-AH, hydrolyzes
PAF, a strong inflammatory mediator, and may thus exert an anti-
inflammatory effect. To examine this theory, we determined the
effects of darapladib on the serum PAF level. As shown in
Figure 2C, no significant differences were evident in the serum
PAF levels between the two groups.
Inhibition of lp-PLA2 significantly reduces the formation
of atherosclerotic lesions
To ascertain the effects of the lp-PLA2 inhibitor on atheroscle-
rotic lesion formation, we detected plaque sizes at the proximal
aorta via Sudan IV staining. As shown in Figure 3, inhibition of lp-
PLA2 induced a significant decrease in the plaque area. Vehicle-
treated mice displayed approximately 3263% plaque coverage,
whereas mice treated with darapladib had 2263% plaque
coverage (Figure 3B).
To evaluate lesion composition, we immunostained the lesions
for macrophages, VSMCs, as well as collagen content. The
macrophage content in lesions of the darapladib group was lower
and the collagen content higher, compared with the vehicle group.
However, the VSMC content was shown no significant difference
between the two groups (Figure 4).
Inhibition of lp-PLA2 attenuates inflammatory gene
expression at the lesion areas
We additionally evaluated the expression of lp-PLA2 and
several inflammatory genes in the arteries using quantitative
realtime PCR. As shown in Figure 5, lp-PLA2 gene expression was
not significantly different between the darapladib and vehicle
groups. However, several inflammatory genes, MCP-1, VCAM-1
and TNF-a, were remarkably reduced in the darapladib group,
compared with the vehicle group. Unexpectedly, ICAM-1, MMP-
2 and MMP-9 expression patterns were comparable between the
two groups (Figure 5).
Discussion
Atherosclerosis contributes to myocardial infarction and stroke,
the principal causes of death in developed societies. Dyslipidemia
and inflammation cooperate to promote atherosclerosis progres-
sion. Statins, widely used in the treatment of atherogenic
dyslipidemia, exert significant beneficial effects on coronary heart
disease, but do not completely diminish cardiovascular risks [13].
Thus, other targets independent of dyslipidemia are urgently
required to decrease cardiovascular risk. The aim of this study was
to evaluate the effects of a specific inhibitor of the new therapeutic
target, lp-PLA2, on atherosclerosis development in high-fat diet
fed mice.
The lp-PLA2 inhibitor has been shown to reduce atheroscler-
ostic plaque formation in diabetes mellitus and hypercholesterol-
emia (DM-HC) pigs [7]. Darapladib treatment resulted in a
considerable decrease in the plaque and necrotic core areas.
Inhibition of lp-PLA2 also induced beneficial effects in clinical
research, as darapladib terminated the increase in necrotic core, a
Figure 2. Inhibition of lp-PLA2 by darapladib decreases serum
hs-CRP and IL-6 levels, but has no significant effects on the
PAF level. After 6 weeks of feeding, serum hs-CRP, IL-6 and PAF levels
were determined using ELISA. *p,0.05 and **p,0.01 vs. vehicle.
doi:10.1371/journal.pone.0023425.g002
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on plaque formation [8].
ApoE-deficient mice have been extensively used to evaluate the
efficacy of anti-atherogenic drugs and the mechanisms of
atherosclerosis progression. As the uptake of lipoprotein particles
is impaired, these mice spontaneously display elevated blood lipid
levels. The high-fat diet leads to increased cholesterol and TG
levels in both VLDL and LDL fractions, as well as lesion
formation. High VLDL and LDL or low HDL levels are known
risk factors of cardiovascular disease. However, treatment with the
lp-PLA2 inhibitor did not alter the plasma lipoprotein levels or
profile. In another study, adenovirus-mediated gene transfer of lp-
PLA2 significantly enhanced the lp-PLA2 level without changing
the lipid profile in mice [11]. Thus, lp-PLA2 exerts a modulatory
role in the progression of atherosclerosis, independent of the
lipoprotein profile.
Several epidemiological studies have shown that the plasma
level and activity of lp-PLA2 increase during the development of
atherosclerosis, supporting its utility as a marker for cardiovascular
risk [14,15,16,17,18]. In the current study, we additionally
demonstrated that the serum lp-PLA2 activity increased in the
vehicle group after high-fat feeding for 6 weeks, but was
significantly inhibited in the darapladib group.
Lp-PLA2 is thought to play an important modulatory role in
atherogenesis due to its catalytic activity in hydrolysis of bioactive
lipids, such as PAF and oxPCs. However, the precise role of lp-
PLA2 is controversial. PAF is a typical pro-inflammatory factor
that contributes to tissue damage and thrombosis formation,
among other effects [19]. From this viewpoint, lp-PLA2 would
exert an anti-atherogenic role by inactivating PAF. However,
there is no evidence that lp-PLA2 hydrolyzes PAF in vivo. In the
present study, inhibition of lp-PLA2 by darapladib did not affect
the serum PAF level. In addition, intravenous administration of
recombinant lp-PLA2 failed to alter PAF-mediated responses in
patients with asthma or septic shock [20,21].
Conversely, considerable evidence has been obtained for pro-
atherogenic roles of lp-PLA2 in vitro and in vivo [2,7,22,23]. Lp-
PLA2 produces two types of inflammatory mediators, lysoPCs and
oxNEFA, via hydrolyzing oxidized phospholipids in oxLDL,
which trigger significant inflammatory responses, such as cell
adhesion, inflammatory gene expression, and cell death [5,24].
Furthermore, in vivo studies have suggested that inhibition of lp-
PLA2 by darapladib decreases the inflammatory burden in
humans and pigs [7,8,23,25]. Here, we examined the inflamma-
tory factors in serum and gene expression of inflammatory
cytokines in lesions. Consistent with earlier in vivo findings, the
inflammatory burden decreased in the darapladib group, com-
pared with that in the vehicle group. Along with previous reports,
our present findings support a pro-inflammatory role of lp-PLA2 in
vivo.
The present study has some limitations, as the detailed
mechanisms underlying the anti-atherogenic effects of the lp-
PLA2 inhibitor remain unclear. Based on the previous and present
data, we suggest that the beneficial effects of darapladib against the
formation of atherosclerosis are possibly attributed to its anti-
inflammation properties. In clinical research, oral darapladib
(160 mg once daily) induced a significant decrease in plasma IL-6
and hs-CRP levels [25]. Similarly, in another clinical report,
inhibition of lp-PLA2 suppressed the hs-CRP level [8]. Further-
more, analysis of coronary gene expression revealed that inhibition
of lp-PLA2 led to a substantial reduction in the expression of many
genes associated with macrophage and T lymphocyte functioning
in pigs [7]. In the present investigation, inhibition of lp-PLA2
attenuated the inflammatory burden in ApoE-deficient mice, as
evident from the decreased serum levels of hs-CRP and IL-6 and
inflammatory gene expression in the darapladib-treated group.
LysoPCs, the products of lp-PLA2 inducing many inflammatory
genes expression has been well established. For instance, lysoPCs
can up-regulate MCP-1 and ICAM-1/VCAM-1 expression in
endothelial cells or VSMCs [6,26,27,28]. It is apparent that
inhibition of lp-PLA2 may decrease arterial lysoPCs abundance
and consequent reduction of inflammatory burden. We did not
measure the lysoPCs in mice aortas in present study; nevertheless,
darapladib treatment was associated with a decrease in elevated
arterial lysoPCs abundance in DM-HC pigs [7]. However, the
possibility that darapladib exerts its anti-atherosclerosis effects
through other mechanisms cannot be excluded. For instance, the
compound may directly reduce the uptake of lipids by macro-
phages, as demonstrated in a previous study by our group [4]. The
beneficial effects may also be induced by the compound itself,
independent of lp-PLA2. Further studies are essential to investigate
the precise mechanisms by which lp-PA2 inhibition triggers anti-
atherosclerosis effects.
Another noteworthy finding is that the collagen content at the
lesion area in the darapladib-treated group was higher than that of
the vehicle group. Vascular remodeling, especially extracellular
matrix (ECM) increase, is thought to stabilize plaques, which may
prevent disruption of lesions [29,30]. Based on the present data,
we propose that darapladib increases the collagen content or
decreases degradation of collagen in the lesion areas, indicating
Figure 3. Inhibition of lp-PLA2 decreases the atherosclerotic
area. (A). Representative en face atherosclerotic aorta preparations
stained with Sudan IV. (B). Comparison of plaque sizes between the
vehicle and darapladib groups (N=13 per group). The area stained with
dye is expressed as a percentage of the total surface area. The mean is
depicted as a single horizontal line.
doi:10.1371/journal.pone.0023425.g003
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23425Figure 4. Composition of atherosclerotic plaques in the aortic sinus. (A) and (B). Representative examples are provided for VSMC-Actin,
macrophage antibody (Mac-2) and trichrome-stained aortic sinus sections. Arrows are indicative of representative regions staining positively for
VSMCs and macrophages. The collagen regions are indicated in blue. The bar indicates 400 mm (A) and 200 mm (B), respectively. (C). Comparison of
VSMC, macrophage and collagen content between the two groups (N=7 per group), *p,0.05 and **p,0.01 vs. vehicle.
doi:10.1371/journal.pone.0023425.g004
Figure 5. Inhibition of lp-PLA2 attenuates inflammatory gene expression at the aortic arch and thoracic-abdominal aortas. Lp-PLA2,
MCP-1, ICAM-1, VCAM-1, TNF-a, MMP-2 and MMP-9 gene expression was determined using quantitative RT-PCR. N=5 per group, *p,0.05, and
**p,0.01 vs. vehicle.
doi:10.1371/journal.pone.0023425.g005
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previous results [31]. As MMPs play pivotal roles in ECM
degradation, we determined MMP-2 and MMP-9 expression
within the lesion areas. Interestingly, no differences were observed
in the MMP expression patterns between the vehicle and
darapladib groups. However, MMP-2 activity was lower at the
lesion area in the darapladib group (unpublished data). Further
studies are needed to explore the interplay between lp-PLA2 and
MMPs.
In summary, our in vivo studies demonstrate that inhibition of lp-
PLA2 by darapladib does not decrease dyslipidemia but
ameliorates the inflammatory burden, resulting in decrease of
atherosclerosis in high-fat diet-fed ApoE-deficient mice. Our
present study validates the feasibility of anti-inflammation
therapeutic strategies for the effective treatment of cardiovascular
disease and the utility of lp-PLA2 as a promising target against
atherosclerosis.
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